[go: up one dir, main page]

WO1999000115A1 - Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases - Google Patents

Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases Download PDF

Info

Publication number
WO1999000115A1
WO1999000115A1 PCT/EP1998/004005 EP9804005W WO9900115A1 WO 1999000115 A1 WO1999000115 A1 WO 1999000115A1 EP 9804005 W EP9804005 W EP 9804005W WO 9900115 A1 WO9900115 A1 WO 9900115A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
vanilloid receptor
receptor complexes
neurodegenerative diseases
compounds
Prior art date
Application number
PCT/EP1998/004005
Other languages
French (fr)
Inventor
Christopher David Benham
John Davis
Andrew Parsons
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to JP50529699A priority Critical patent/JP2002511866A/en
Priority to CA002295089A priority patent/CA2295089A1/en
Priority to EP98936402A priority patent/EP1003491A1/en
Publication of WO1999000115A1 publication Critical patent/WO1999000115A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the use of antagonists or partial agonists of vanilloid receptors or vanilloid receptor complexes in the treatment or prophylaxis of neurodegenerative diseases.
  • Vanilloids are a class of natural and synthetic compounds which are characterised by the presence of a vanillyl group or a functionally equivalent group.
  • vanilloid receptor or vanilloid receptor complex is used herein to define a single protein or complex of more than one protein, or other components, whose function is modulated by a vanilloid compound.
  • vanilloid compounds of different structures have been disclosed in the literature, for example European Patent Specifications Nos. 347000 and 401903, UK Patent Specification No. 2226313, and PCT Patent Specification No. WO92/09285.
  • vanilloid compounds or vanilloid receptor modulators are capsaicin, namely trans 8-methyl-N-vanillyl-6-nonenamide, isolated from the pepper plant, capsazepine ( Tetrahedron ,Vol 53,No 13,pp4791-4814 1997 ) and olvanil, N-(3-methoxy- 4-hydroxy-benzyl)oleamide ( J.Med. Chem. 1993, 36, 2595-2604).
  • capsaicin and its vanilloid derivatives have been extensively studied and numerous proposals have been made in regard to possible therapeutic uses for the compounds including use as an analgesic or anti-inflammatory agent (GB 2226313). Such compounds have also been proposed for the treatment of herpes simplex infections (EP 347000) and respiratory diseases and disorders (EP 401903).
  • the analgesic effect of capsaicin is characterised by an initial nociceptive effect from the compound but subsequently by an analgesic effect. Such effects can be blocked by capsazepine which acts effectively as an antagonist to the relevant capsaicin receptor.
  • Another vanilloid compound, olvanil acts as a partial antagonist/partial agonist.
  • neurodegenerative disease is used herein to denote a disease or disorder which is characterised by loss of cells which normally contribute to the structure and function of the central or peripheral nervous system.
  • diseases which may be treated in accordance with the invention include stroke, motor neurone disease, Parkinson's disease, Alzheimers disease, AIDS-related dementia , Lewy Body disease , brain or nerve injuries, peripheral neuropathies and prion disease.
  • R ! and R ⁇ > which may be the same or different, each represents hydrogen, C [.5 alkyl (e.g. methyl or ethyl), C [_6 alkoxy, halogen (e.g. chlorine) or trifluoromethyl;
  • X represents oxygen, sulphur, CH2 or a chemical bond
  • Z represents a C ⁇ _g alkylene group
  • R3 and R 4 which may be the same or different, each represents hydrogen, C ⁇ _ ⁇ alkyl (e.g. methyl or ethyl) or R ⁇ and R 4 together with the adjacent nitrogen atom, form a 4- to 7- membered heterocyclic ring optionally containing one or more (e.g. 1, 2 or 3) further heteroatoms selected from oyxgen, nitrogen and sulphur, and optionally substituted for example by one or more C ⁇ . alkyl (e.g methyl or ethyl) or hydroxy-C g alkyl (e.g. 2- hydroxyethyl).
  • the group Z which may be straight or branched, preferably contains three carbon atoms.
  • heterocyclic ring examples include pyrrolidino, piperidino , piperazino or morpholino.
  • Particularly preferred examples of compounds for use in accordance with the invention include vanilloid compounds and especially capsazepine and olvanil referred to above.
  • the compounds of the present invention are usually administered as a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound according to the invention and a physiologically acceptable carrier.
  • the compounds may be administered by any convenient method, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
  • the compounds which are active when given orally ban be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • the formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
  • Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device.
  • the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted.
  • the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air.
  • compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
  • compositions suitable for transdermal administration include ointments, gels and patches.
  • composition is in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains preferably from 1 to 100 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the invention.
  • the physiologically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 2 and 200 mg, preferably between 50 mg and 150 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.2 mg and 20 mg, preferably between 0.5 mg and 5 mg, of the compound, the compound being administered 1 to 4 times per day.
  • a daily dosage regimen for an adult patient
  • an oral dose of between 2 and 200 mg, preferably between 50 mg and 150 mg
  • an intravenous, subcutaneous, or intramuscular dose of between 0.2 mg and 20 mg, preferably between 0.5 mg and 5 mg, of the compound, the compound being administered 1 to 4 times per day.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • the neuroprotective effect of the above vanilloid compounds according to the invention is illustrated by the following investigation of the ability of the vanilloid compounds olvanil and capsazepine to protect the neuronal HT-4 cell line from glutamate induced cytotoxicity.
  • MTT assay Hanesen, M.B., Nielsen, S.E. and Berg, K.., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Methods, 1 19 (1989) 203-210.
  • MTT assays cells were plated into 96- well plates at 5 x 10 3 cells/well in complete medium (DMEM/10 FCS/2mM glutamine), and 24hr later the experimental agents were added. Test compounds were added at the final concentration shown in DMEM/10%FCS/2mM glutamine.
  • E16 rat primary cortical neurones were plated at 60x10 ⁇ cells/well in complete medium
  • DMEM:F12/5%HS/10%FCS/2mM glutamine The cells were used within 48hr of plating. Test compounds were added at the final concentration shown in DMEM/10%FCS/2mM glutamine. Vehicles showed no effect at the dilutions used (data not shown). Cell viability was assessed by the ability of cells to reduce MTT, which was assayed a further 24hr after the addition of the experimental agents, according to the method of Hansen et al.. Capsazepine demonstrated a neuroprotective effect
  • Organotypic hippocampal slice cultures were prepared according to Stoppini, L., Buchs, P.A. & Muller, D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37 (1991) 173-182. After 9-12 days the cultures were transferred to 6- well plates containing glucose-free medium, with or without agents to be tested, saturated with 95% N2/5 CO2 and placed in an anaerobic chamber, preequilibrated and maintained at 37°C, 100% humidity, 95% N2/5 CO2, for 45mins. The plates were then removed from the chamber and the cultures transferred to fresh serum-free medium containing

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of antagonist or partial agonists of the vanilloid receptor complexes such as capsazepine or olvanil for the treatment of neurodegenerative diseases.

Description

USE OF ANTAGONISTS OR PARTIAL AGONISTS OF THE VANILLOID RECEPTOR COMPLEXES FOR TREAΗNG NEURODEGENERAΗVE DISEASES
The present invention relates to the use of antagonists or partial agonists of vanilloid receptors or vanilloid receptor complexes in the treatment or prophylaxis of neurodegenerative diseases.
Vanilloids are a class of natural and synthetic compounds which are characterised by the presence of a vanillyl group or a functionally equivalent group.
The term "vanilloid receptor or vanilloid receptor complex" is used herein to define a single protein or complex of more than one protein, or other components, whose function is modulated by a vanilloid compound.
A wide variety of vanilloid compounds of different structures have been disclosed in the literature, for example European Patent Specifications Nos. 347000 and 401903, UK Patent Specification No. 2226313, and PCT Patent Specification No. WO92/09285. Particularly notable examples of vanilloid compounds or vanilloid receptor modulators are capsaicin, namely trans 8-methyl-N-vanillyl-6-nonenamide, isolated from the pepper plant, capsazepine ( Tetrahedron ,Vol 53,No 13,pp4791-4814 1997 ) and olvanil, N-(3-methoxy- 4-hydroxy-benzyl)oleamide ( J.Med. Chem. 1993, 36, 2595-2604). The pharmacological effects of capsaicin and its vanilloid derivatives have been extensively studied and numerous proposals have been made in regard to possible therapeutic uses for the compounds including use as an analgesic or anti-inflammatory agent (GB 2226313). Such compounds have also been proposed for the treatment of herpes simplex infections (EP 347000) and respiratory diseases and disorders (EP 401903). The analgesic effect of capsaicin is characterised by an initial nociceptive effect from the compound but subsequently by an analgesic effect. Such effects can be blocked by capsazepine which acts effectively as an antagonist to the relevant capsaicin receptor. Another vanilloid compound, olvanil, acts as a partial antagonist/partial agonist.
We have now found that compounds which are antagonists (Walpole et al. 1994, J Med Chem 37: 1942- 1954) or partial agonists (Janusz et al., 1993, J Med Chem 36: 2592-2604) for vanilloid receptors or vanillod receptor complexes ( such compounds being hereinafter identified as compounds according to the invention) are capable of exerting a neuroprotective effect and are therefore useful in the treatment or prophylaxis of neurodesenerative diseases. According to one feature of the present invention, we provide compounds according to the invention for use in the treatment or prophylaxis of neurodegenerative diseases.
According to a further feature of the present invention we provide the use of a compound according to the invention in the manufacture of a medicament for the treatment or prophylaxis of neurodegenerative diseases.
According to a still further feature of the present invention we provide a method for the treatment or prophylaxis of neurodegenerative diseases which comprises administering to a human subject an effective amount of a compound according to the invention.
The term "neurodegenerative disease " is used herein to denote a disease or disorder which is characterised by loss of cells which normally contribute to the structure and function of the central or peripheral nervous system. Examples of such diseases which may be treated in accordance with the invention include stroke, motor neurone disease, Parkinson's disease, Alzheimers disease, AIDS-related dementia , Lewy Body disease , brain or nerve injuries, peripheral neuropathies and prion disease.
Examples of compounds which may be employed in accordance with the invention include compounds of formula (I):
Figure imgf000004_0001
in which
R ! and R^> which may be the same or different, each represents hydrogen, C [.5 alkyl (e.g. methyl or ethyl), C [_6 alkoxy, halogen (e.g. chlorine) or trifluoromethyl;
X represents oxygen, sulphur, CH2 or a chemical bond;
Z represents a C ι_g alkylene group; R3 and R4, which may be the same or different, each represents hydrogen, C ι_β alkyl (e.g. methyl or ethyl) or R^ and R4 together with the adjacent nitrogen atom, form a 4- to 7- membered heterocyclic ring optionally containing one or more (e.g. 1, 2 or 3) further heteroatoms selected from oyxgen, nitrogen and sulphur, and optionally substituted for example by one or more C{. alkyl (e.g methyl or ethyl) or hydroxy-C g alkyl (e.g. 2- hydroxyethyl).
The group Z, which may be straight or branched, preferably contains three carbon atoms.
Examples of the above heterocyclic ring include pyrrolidino, piperidino , piperazino or morpholino.
Specific examples of compounds of formula (I) include: 10- [2-methyl-3-(pyrrolidin- 1 -yl)propyl]- 1 OH-phenoxazine
10-[3-(dimethylamino)-2-methylpropyl]-2-methyl-10H-phenoxazine
10-[3-(dipropylamino)propyl]-10H-phenoxazine
2-chloro- 10-[3-(pyrrolidin- 1 -y l)propy 1]- 1 OH-phenothiazine
10-(3-diethylaminopropyl)- 1 OH-phenoxazine 10-[3-(4-methylpiperazin- 1 -yl)propyl] - 1 OH-phenoxazine
10-[3-(diethylamino)-2-methylpropyl] - 1 OH-phenoxazine
10-[3-(4-(2-hydroxyethyl)piperazin-l-yl)propyl]-l OH-phenoxazine
2-ethyl- 10- [2-methyl-3-(pyrrolidin- 1 -yl)propy 1]- 1 OH-phenoxazine
10-[3-(dimethylamino)-2-methylpropyl]-10H-phenoxazine
The above compounds may be prepared in accordance with the methods described by
Schmolka et al, Synthesis, 1984, (1), 29-31 or by methods analogous thereto.
Particularly preferred examples of compounds for use in accordance with the invention include vanilloid compounds and especially capsazepine and olvanil referred to above.
These compounds may be prepared in accordance with the processes disclosed in the above references.
For use in medicine, the compounds of the present invention are usually administered as a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound according to the invention and a physiologically acceptable carrier.
The compounds may be administered by any convenient method, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly. The compounds which are active when given orally ban be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air. or an organic propellant such as a fluoro-chlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomiser. Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
Compositions suitable for transdermal administration include ointments, gels and patches.
Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.
Each dosage unit for oral administration contains preferably from 1 to 100 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the invention.
The physiologically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 2 and 200 mg, preferably between 50 mg and 150 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.2 mg and 20 mg, preferably between 0.5 mg and 5 mg, of the compound, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.
Examples
Neuroprotective Effect against Glutamate-induced Cvtotoxicitv in HT-4 Cell Line
The neuroprotective effect of the above vanilloid compounds according to the invention is illustrated by the following investigation of the ability of the vanilloid compounds olvanil and capsazepine to protect the neuronal HT-4 cell line from glutamate induced cytotoxicity.
Cell viability was assayed using the MTT assay (Hansen, M.B., Nielsen, S.E. and Berg, K.., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Methods, 1 19 (1989) 203-210.) or by morphology. For MTT assays, cells were plated into 96- well plates at 5 x 103 cells/well in complete medium (DMEM/10 FCS/2mM glutamine), and 24hr later the experimental agents were added. Test compounds were added at the final concentration shown in DMEM/10%FCS/2mM glutamine. Vehicles showed no effect at the dilutions used (data not shown) and glutamate was added to give a final concentration of 5mM. Cell viability was assessed by the ability of cells to reduce MTT, which was assayed a further 24hr after the addition of the experimental agents, according to the method of Hansen et al. Capsazepine and olvanil demonstrated a neuroprotective effect.
Neuroprotective Effect against Glutamate-induced Cvtotoxicity in Rat Cortical Neurones
Cell viability was assayed using the MTT assay (Hansen et al. 1989), or by morphology. E16 rat primary cortical neurones were plated at 60x10^ cells/well in complete medium
(DMEM:F12/5%HS/10%FCS/2mM glutamine). The cells were used within 48hr of plating. Test compounds were added at the final concentration shown in DMEM/10%FCS/2mM glutamine. Vehicles showed no effect at the dilutions used (data not shown). Cell viability was assessed by the ability of cells to reduce MTT, which was assayed a further 24hr after the addition of the experimental agents, according to the method of Hansen et al.. Capsazepine demonstrated a neuroprotective effect
Protective effect for hippocampal slice cultures challenged with oxygen/glucose deprivation.
Organotypic hippocampal slice cultures were prepared according to Stoppini, L., Buchs, P.A. & Muller, D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37 (1991) 173-182. After 9-12 days the cultures were transferred to 6- well plates containing glucose-free medium, with or without agents to be tested, saturated with 95% N2/5 CO2 and placed in an anaerobic chamber, preequilibrated and maintained at 37°C, 100% humidity, 95% N2/5 CO2, for 45mins. The plates were then removed from the chamber and the cultures transferred to fresh serum-free medium containing
6microgram/ml propidium iodide and agent. The cultures were then placed back into the
CO2 incubator for 23hrs prior to analysis using NIH IMAGE 1.62. Capsazepine demonstrated a neuroprotective effect.

Claims

Claims
1. Antagonists or partial agonists for vanilloid receptor complexes for use in the treatment or prophylaxis of neurodegenerative diseases.
2. Capsazepine or olvanil for use as claimed in claim 1.
3. Compounds as claimed in claim 1 or claim 2 in which the neurodegenerative disease is stroke, motor neurone disease, Parkinsons disease, Alzheimers disease, AIDS-related dementia , Lewy Body disease , brain or nerve injuries, peripheral neuropathies and prion disease
4. The use of antagonists or partial agonists for vanilloid receptor complexes in the manufacture of a medicament for the treatment or prophylaxis of neurodegenerative diseases.
5. The use of capsazepine or olvanil as claimed in claim 4.
6. The use as claimed in claim 4 or claim 5 in which the neurodegenerative disease is as defined in claim 3.
7. A method for the treatment or prophylaxis of neurodegenerative diseases which comprises administering to a human subject an effective amount of an antagonist or partial agonist for vanilloid receptor complexes .
8. A method as claimed in claim 7 in which the said antagonist or partial agonist is capsazepine or olvanil .
9. A method as claimed in claim 7 or claim 8 in which the neurodegenerative disease is as defined in claim 3.
10. A pharmaceutical composition comprising an antagonist or partial agonist for vanilloid receptor complexes and a physiologically acceptable carrier.
PCT/EP1998/004005 1997-06-27 1998-06-18 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases WO1999000115A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP50529699A JP2002511866A (en) 1997-06-27 1998-06-18 Use of an antagonist or partial agonist of the vanilloid receptor complex for the treatment of neurodegenerative diseases
CA002295089A CA2295089A1 (en) 1997-06-27 1998-06-18 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases
EP98936402A EP1003491A1 (en) 1997-06-27 1998-06-18 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713484.5A GB9713484D0 (en) 1997-06-27 1997-06-27 Neuroprotective vanilloid compounds
GB9713484.5 1997-06-27

Publications (1)

Publication Number Publication Date
WO1999000115A1 true WO1999000115A1 (en) 1999-01-07

Family

ID=10814943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/004005 WO1999000115A1 (en) 1997-06-27 1998-06-18 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases

Country Status (5)

Country Link
EP (1) EP1003491A1 (en)
JP (1) JP2002511866A (en)
CA (1) CA2295089A1 (en)
GB (1) GB9713484D0 (en)
WO (1) WO1999000115A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1160254A1 (en) * 2000-05-31 2001-12-05 Pfizer Inc. Human vanilloid receptor-like proteins
US6444440B1 (en) 1997-03-07 2002-09-03 Human Genome Sciences, Inc. Vanilloid receptor-2
WO2002044210A3 (en) * 2000-12-01 2003-11-06 Bristol Myers Squibb Co Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
WO2003095420A1 (en) 2002-05-08 2003-11-20 Bayer Healthcare Ag Hydroxy tetrahydro-naphthalenylurea derivatives
KR100433940B1 (en) * 2000-08-22 2004-06-04 주식회사 뉴로넥스 Pharmaceutical Composition for Prevention and Treatment of Rheumatic Arthritis or Allergic Diseases Comprising Capsazepine with Inhibitory Activity of PAF receptor as Active Ingredient
JP2004182599A (en) * 2001-12-18 2004-07-02 Daicho Kikaku:Kk Muscle-strengthening drug and antiinflammatory drug
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
US6906178B2 (en) 1998-08-11 2005-06-14 Human Genome Sciences, Inc. Vanilloid receptor-2
WO2006005472A1 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1)
US7067553B2 (en) * 2000-08-21 2006-06-27 Pacific Corporation Thiourea compounds and the pharmaceutical compositions containing the same
US7074799B2 (en) 2002-01-17 2006-07-11 Neurogen Corporation Substituted quinazolin-4-ylamine analogues
WO2007102660A1 (en) * 2006-03-08 2007-09-13 Sungkyunkwan University Foundation For Corporate Collaboration Vanilloid receptor antagonist for prevention and treatment of drug dependence and addiction
EP2048132A1 (en) 2003-10-01 2009-04-15 Xention Limited Tetrahydro-naphthalene and urea derivatives
US7582651B2 (en) 2002-07-11 2009-09-01 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
US7618993B2 (en) 2005-12-23 2009-11-17 Astrazeneca Ab Compounds
US7645784B2 (en) 2003-05-16 2010-01-12 Astrazeneca Ab Benzimidazole derivatives
US7683076B2 (en) 2003-11-08 2010-03-23 Bayer Schering Pharma Aktiengesellschaft Tetrahydro-quinolinylurea derivatives
US7906654B2 (en) 2006-08-11 2011-03-15 Astrazeneca Ab Benzimidazole derivatives
US8071650B2 (en) 2000-08-21 2011-12-06 Pacific Corporation Thiourea derivatives and the pharmaceutical compositions containing the same

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010215563A (en) * 2009-03-17 2010-09-30 Kao Corp Lkb1 activator
CN110876813A (en) * 2019-12-09 2020-03-13 北京大学 Chili horizontal hydrogel and application thereof in repairing peripheral nerve injury and restoring motor function

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132113A1 (en) * 1983-07-14 1985-01-23 The Procter & Gamble Company Compositions useful for producing analgesia
US4833138A (en) * 1987-10-23 1989-05-23 Washington University Phenothiazinealkaneamines for treatment of neurotoxic injury
EP0347000A2 (en) * 1988-06-17 1989-12-20 The Procter & Gamble Company The use of vanilloids for the manufacture of a medicament for treating herpes simplex infections
WO1996004915A1 (en) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
WO1997017077A1 (en) * 1995-11-06 1997-05-15 L'oreal Topical composition containing capsazepine
WO1998020867A1 (en) * 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132113A1 (en) * 1983-07-14 1985-01-23 The Procter & Gamble Company Compositions useful for producing analgesia
US4833138A (en) * 1987-10-23 1989-05-23 Washington University Phenothiazinealkaneamines for treatment of neurotoxic injury
EP0347000A2 (en) * 1988-06-17 1989-12-20 The Procter & Gamble Company The use of vanilloids for the manufacture of a medicament for treating herpes simplex infections
WO1996004915A1 (en) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
WO1997017077A1 (en) * 1995-11-06 1997-05-15 L'oreal Topical composition containing capsazepine
WO1998020867A1 (en) * 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 97, no. 25, 20 December 1982, Columbus, Ohio, US; abstract no. 207769, I. PLATONOV ET AL.: "EFFECT OF PHENOTHIAZINE DERIVATIVES ON THE DEVELOPMENT OF EXPERIMENTAL TRAUMATIC BRAIN EDEMA" XP002085074 *
DRAY A: "NEUROPHARMACOLOGICAL MECHANISMS OF CAPSAICIN AND RELATED SUBSTANCES", BIOCHEMICAL PHARMACOLOGY, vol. 44, no. 4, 18 August 1992 (1992-08-18), pages 611 - 615, XP000576776 *
FARMAKOL. TOKSIKOL., vol. 45, no. 5, 1982, MOSCOW, pages 42 - 45 *
G. ACS ET AL.: "TRIFLUOROPERAZINE MODULATES (3H)RESINIFERATOXIN BINDING BY HUMAN AND RAT VANILLOID (CAPSAICIN) RECEPTORS AND AFFECTS 45CA UPTAKE BY ADULT RAT DORSAL ROOT GANGLION NEURONES", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 274, no. 3, 1995, pages 1090 - 1098, XP002085071 *
M. UEDA ET AL.: "DETECTION OF CAPSAICIN-EVOKED RELEASE OF GLUTAMATE FROM SPINAL DORSAL HORN SLICES OF RAT WITH ON-LINE MONITORING SYSTEM", NEUROSCIENCE LETTERS, vol. 155, no. 2, 1993, pages 179 - 182, XP002085073 *
RITTER ET AL.: "CAPSAICIN-INDUCED NEURONAL DEGENERATION IN THE BRAIN AND RETINA OF PREWEANLING RATS", JOURNAL OF COMPARATIVE NEUROLOGY, vol. 296, no. 3, 1990, pages 447 - 461, XP002085072 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444440B1 (en) 1997-03-07 2002-09-03 Human Genome Sciences, Inc. Vanilloid receptor-2
US6906178B2 (en) 1998-08-11 2005-06-14 Human Genome Sciences, Inc. Vanilloid receptor-2
EP1160254A1 (en) * 2000-05-31 2001-12-05 Pfizer Inc. Human vanilloid receptor-like proteins
US8071650B2 (en) 2000-08-21 2011-12-06 Pacific Corporation Thiourea derivatives and the pharmaceutical compositions containing the same
US7067553B2 (en) * 2000-08-21 2006-06-27 Pacific Corporation Thiourea compounds and the pharmaceutical compositions containing the same
KR100433940B1 (en) * 2000-08-22 2004-06-04 주식회사 뉴로넥스 Pharmaceutical Composition for Prevention and Treatment of Rheumatic Arthritis or Allergic Diseases Comprising Capsazepine with Inhibitory Activity of PAF receptor as Active Ingredient
WO2002044210A3 (en) * 2000-12-01 2003-11-06 Bristol Myers Squibb Co Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
JP2004182599A (en) * 2001-12-18 2004-07-02 Daicho Kikaku:Kk Muscle-strengthening drug and antiinflammatory drug
US7304059B2 (en) 2002-01-17 2007-12-04 Neurogen Corporation Substituted quinazolin-4-ylamine analogues
US7074799B2 (en) 2002-01-17 2006-07-11 Neurogen Corporation Substituted quinazolin-4-ylamine analogues
WO2003095420A1 (en) 2002-05-08 2003-11-20 Bayer Healthcare Ag Hydroxy tetrahydro-naphthalenylurea derivatives
US7582651B2 (en) 2002-07-11 2009-09-01 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
US7645784B2 (en) 2003-05-16 2010-01-12 Astrazeneca Ab Benzimidazole derivatives
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
WO2005002551A3 (en) * 2003-07-03 2005-10-06 Bayer Healthcare Ag Vanilloid receptor (vr) 1 inhibitors for treatment of human immunodeficiency virus (hiv)-mediated pain states
EP2048132A1 (en) 2003-10-01 2009-04-15 Xention Limited Tetrahydro-naphthalene and urea derivatives
US7683076B2 (en) 2003-11-08 2010-03-23 Bayer Schering Pharma Aktiengesellschaft Tetrahydro-quinolinylurea derivatives
WO2006005472A1 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1)
US7618993B2 (en) 2005-12-23 2009-11-17 Astrazeneca Ab Compounds
US8168668B2 (en) 2005-12-23 2012-05-01 Astrazeneca Ab Compounds
WO2007102660A1 (en) * 2006-03-08 2007-09-13 Sungkyunkwan University Foundation For Corporate Collaboration Vanilloid receptor antagonist for prevention and treatment of drug dependence and addiction
US7906654B2 (en) 2006-08-11 2011-03-15 Astrazeneca Ab Benzimidazole derivatives
US8093402B2 (en) 2006-08-11 2012-01-10 Astrazeneca Ab Benzimidazole derivatives

Also Published As

Publication number Publication date
EP1003491A1 (en) 2000-05-31
CA2295089A1 (en) 1999-01-07
GB9713484D0 (en) 1997-09-03
JP2002511866A (en) 2002-04-16

Similar Documents

Publication Publication Date Title
WO1999000115A1 (en) Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases
RU2330661C2 (en) Combinations containing antidiarrheal agent and epothylon or epothylon derivatives
RU2157205C2 (en) Application of riluzole for treatment of neurological aids and a method for preparation of drug
RU2221563C2 (en) Pharmaceutical composition for treatment of parkinson's disease and parkinson's syndrome, method for its preparing, method for treatment of parkinson's disease and parkinson's syndrome
LU87314A1 (en) NEW BRIDGED PIPERIDINES, THEIR PREPARATION AND THEIR USE AS MEDICINES
EP0975218A1 (en) Nucleophile substituted ecteinascidins and n-oxide ecteinascidins
BG99700A (en) APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTIAZOLE FOR THE TREATMENT OF DEPRESSION
JPH0558894A (en) Antitumor agent
US4208417A (en) Indole derivatives and their use as anxiolytics
KR0178762B1 (en) New Pharmaceutical Uses of Certain Indole Derivatives and Pharmaceutical Compositions Containing the Same
ITMI941463A1 (en) MORPHINOID HETEROCYCLE-CONDENSER DERIVATIVES
KR930007252B1 (en) Pharmaceutical composition for treatment of depression
DK160047B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 3-IMINO-DIBENZOOEC, FAAIMIDAZOOE1,5-AAAAZEPINES AND -DIBENZOOEB, FAAIMIDAZOOE1,5-DAAOE1,4AAOXAZEPINES AND THIAZEPINES
NZ189159A (en) Oral antihypertensive compositions containing proline derivatives
US6399650B2 (en) Method for improving disturbancies of activities of daily living after stroke
ITMI951417A1 (en) PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR THEIR PREPARATION
JPS6222785A (en) Novel 2-oxopyrrolidine compound and salt thereof, and preventing and treating agent for cerebral dysfunction containing said compound and salt as active constituent
JPH0211543A (en) Polycyclic amine derivative useful as brain blood vessel agent
AU696927B2 (en) Methods for minimizing bone loss
AU5800900A (en) Medicament for treatment of neuropathies
US20020032192A1 (en) Treatment of vasodilatory headache
US4085218A (en) Elevating mood in geriatric patients
JPS61254587A (en) Novel 2-oxopyrrolidine compound and salt thereof, production thereof, and preventive and remedy for cerebral function disorder, containing said compound as active component
KR0150182B1 (en) 7-[(substituted)amino]-8-[(substituted)carbonyl]-methylamino-1-oxaspiro(4,5)decanes as antiinflammatory agent
AU745225B2 (en) Cytotoxic pyridoacridine alkaloids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09446053

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2295089

Country of ref document: CA

Ref country code: CA

Ref document number: 2295089

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998936402

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998936402

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936402

Country of ref document: EP